CA2223489A1 - Method for treating cancer using ahpn - Google Patents

Method for treating cancer using ahpn Download PDF

Info

Publication number
CA2223489A1
CA2223489A1 CA002223489A CA2223489A CA2223489A1 CA 2223489 A1 CA2223489 A1 CA 2223489A1 CA 002223489 A CA002223489 A CA 002223489A CA 2223489 A CA2223489 A CA 2223489A CA 2223489 A1 CA2223489 A1 CA 2223489A1
Authority
CA
Canada
Prior art keywords
ahpn
cells
cell
mda
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002223489A
Other languages
English (en)
French (fr)
Inventor
Joseph A. Fontana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2223489A1 publication Critical patent/CA2223489A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002223489A 1995-07-17 1996-07-17 Method for treating cancer using ahpn Abandoned CA2223489A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US146595P 1995-07-17 1995-07-17
US60/001,465 1995-07-17

Publications (1)

Publication Number Publication Date
CA2223489A1 true CA2223489A1 (en) 1997-02-06

Family

ID=21696159

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002223489A Abandoned CA2223489A1 (en) 1995-07-17 1996-07-17 Method for treating cancer using ahpn

Country Status (5)

Country Link
EP (1) EP0850067A4 (ja)
JP (1) JP2000506489A (ja)
AU (1) AU701790B2 (ja)
CA (1) CA2223489A1 (ja)
WO (1) WO1997003682A1 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US6462064B1 (en) 1996-07-08 2002-10-08 Galderma Research & Development S.N.C. Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias
RU2209626C2 (ru) * 1996-07-08 2003-08-10 Галдерма Ресерч энд Девелопмент, С.Н.С. Производные адамантила, вызывающие апоптоз, и их использование в качестве противораковых агентов
EA200200311A1 (ru) 1999-08-31 2002-08-29 Максиа Фармасьютикалз, Инк. Бензилиден-тиазолидиндионы и аналоги и их применение для лечения диабета
MXPA03008117A (es) 2001-03-07 2004-11-12 Incyte San Diego Inc Derivados heterociclicos para el tratamiento del cancer y otras enfermedades proliferativas.
CA2473156A1 (en) 2001-03-08 2002-09-19 Incyte San Diego, Inc. Rxr activating molecules
DE10255861A1 (de) * 2002-11-29 2004-06-17 Axxima Pharmaceuticals Ag Gegen Hepatitis C-Virusinfektionen nützliche Verbindungen und Substanzen
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
EP1456187A4 (en) 2001-11-15 2005-02-09 Incyte San Diego Inc N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTERINEMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDER, CANCER AND OTHER DISEASES
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
JP2006514094A (ja) * 2002-11-29 2006-04-27 ゲーペーツェー バイオテック アクチェンゲゼルシャフト Ｃ型肝炎ウイルス感染に対して有用な製剤
US20090117203A1 (en) * 2006-03-23 2009-05-07 Tmrc Co., Ltd. Kit for cancer treatment and pharmaceutical composition for cancer treatment
WO2007148804A1 (ja) * 2006-06-23 2007-12-27 Rohto Pharmaceutical Co., Ltd. ヒアルロン酸産生促進能を有する組成物
EP3301085A1 (en) 2016-09-29 2018-04-04 Biogem S.Ca.R.L. Retinoid derivatives with antitumor activity
WO2022229017A1 (en) 2021-04-27 2022-11-03 Biogem S.C.A R.L. Adamantyl retinoid derivative with anticancer activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU85849A1 (fr) * 1985-04-11 1986-11-05 Cird Derives benzonaphtaleniques,leur procede de preparation et leur application dans les domaines pharmaceutiques et cosmetiques

Also Published As

Publication number Publication date
EP0850067A4 (en) 1999-12-15
AU6494996A (en) 1997-02-18
WO1997003682A1 (en) 1997-02-06
AU701790B2 (en) 1999-02-04
EP0850067A1 (en) 1998-07-01
JP2000506489A (ja) 2000-05-30

Similar Documents

Publication Publication Date Title
AU701790B2 (en) Method for treating cancers using 6-{3-{1-adamantyl}- 4-hydroxyphenyl}
US6130230A (en) Therapeutic combinations of RAR antagonists and RXR agonists and use thereof
Supino et al. Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression
WO1998008546A9 (en) Therapeutic combinations of rar antagonists and rxr agonists and use thereof
US20090093546A1 (en) Method and Pharmaceutical Compositions for Treatment of Anti-Estrogen Resistant Breast Cancer Using RXR Modulators
Kim et al. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP
US20240279173A1 (en) Compounds and Methods for Inhibiting CYP26 Enzymes
Zhu Vitamin A and its derivatives-retinoic acid and retinoid pharmacology
US6211239B1 (en) Method for treating or preventing breast cancer or leukemia using 6-[3-[1-adamantyl]-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN)
Makishima et al. Induction of differentiation in acute promyelocytic leukemia cells by 9-cis retinoic acid α-tocopherol ester (9-cis tretinoin tocoferil)
Muñiz-Hernández et al. Alterations in retinoic acid receptors in non-small cell lung cancer and their clinical implications
US20040122080A1 (en) Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
WO2008022505A1 (fr) Utilisation de rubescensine a et de ses dérivés en pharmacie
WO2001078700A2 (en) Compositions for use in modulating immune system function comprising at least one retrinoid and at least one cytokine
Tsiklakis et al. The therapeutic effect of an aromatic retinoid (RO-109359) on hamster buccal pouch carcinomas
Pandey et al. RXRα: Novel Target for Prostate Cancer
JP3824422B2 (ja) レチノイン酸の活性増強剤
EP1383491A2 (en) Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
WO2005027888A1 (fr) Utilisation de constituants efficaces issus de la rhubarbe dans la fabrication d'un medicament favorisant l'apoptose induite par as2o3
Tohda et al. The effects of retinoic acid analogs on the blast cells of acute myeloblastic-leukemia in culture
Wu Critical role for retinoid nuclear receptors RAR and RXR in determining the sensitivity of human ovarian cancer cell lines to retinoid treatment
AU2002305072A1 (en) Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
JPH1072345A (ja) ９−シス−レチノイン酸−α−トコフェロールエステルを含有する白血病治療剤
Drucker Retinoids in the Prevention and Treatment of Skin Cancer
Chomienne Molecular Basis for Retinoic Acid Effects in Acute Promyelocytic Leukemia

Legal Events

Date Code Title Description
FZDE Dead